This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bittl, J. A. Search for Related Content PubMed PubMed Citation Articles by Bittl, J. A. Pubmed/NCBI databases Medline Plus Health Information Angioplasty Kidney Diseases Related Collections Peripheral vascular disease Aggregation Platelet function inhibitors Clinical Studies Catheter-based coronary interventions: stents Angiography Platelets

(Circulation. 2008;117:2724-2726.)
© 2008 American Heart Association, Inc.

Editorial

Damage Control for Renal Artery Stenting

John A. Bittl, MD

From the Munroe Regional Medical Center, Ocala, Fla.

Correspondence to John A. Bittl, MD, Ocala Heart Institute, 13013 Hwy 475, Ocala, FL 34480. E-mail jabittl@mac.com

Key Words: Editorials • arteriosclerosis • kidney • stenosis • stents

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Chronic kidney disease is associated with an increased risk of death in ambulatory patients,¹ patients with heart disease,² and in those undergoing cardiac procedures.³ Slowing the progression of kidney damage should improve survival.

Article p 2752

Stenting of atherosclerotic renal artery stenoses is commonly performed in an attempt to preserve renal function and control blood pressure. The number of Medicare recipients undergoing renal artery angioplasty or stent placement has increased strikingly from 7660 cases in 1996 to 18 520 cases in 2000,⁴ but evidence of benefit remains "sparse and inconclusive."⁵

In this issue of Circulation, Cooper and colleagues report the results of a randomized trial of patients undergoing renal artery stenting to determine whether a filter-based embolic protection device (EPD), the platelet glycoprotein inhibitor abciximab, or both in combination improves renal function.⁶ The results were more negative than anticipated. Glomerular filtration rates (GFR) worsened 30 days after renal stenting in 3 treatment groups and remained unchanged in the fourth group treated with combination therapy (see Table). Secondary comparisons among the treatment groups suggested that the combination of an EPD with abciximab caused the smallest changes in GFR, but no treatment could improve renal function over that existing at baseline before renal artery stenting was carried out.

View this table:   Table. Summary Results of the Primary (1°) End Point of Absolute Change in Glomerular Filtration Rate (GFR) and Percentage Change From Baseline to 30 Days After Renal Artery Stenting Plus Abciximab, Filter-Based Embolic Protection, or Both

The investigators estimated GFR from . . . [Full Text of this Article]